Cargando…

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors

BACKGROUND: We evaluated the risk of sampling errors in specimens of biopsy size, which may be caused by heterogeneous overexpression of Her2/neu in gastric cancer (GC). PATIENTS AND METHODS: The study cohort comprised 454 gastrectomy patients with adenocarcinoma of the stomach or esophago-gastric j...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warneke, V. S., Behrens, H.-M., Böger, C., Becker, T., Lordick, F., Ebert, M. P. A., Röcken, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574551/ https://www.ncbi.nlm.nih.gov/pubmed/23139264 http://dx.doi.org/10.1093/annonc/mds528

Ejemplares similares

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
por: Behrens, Hans-Michael, et al.
Publicado: (2015)

The Spatial Distribution of LGR5(+) Cells Correlates With Gastric Cancer Progression
por: Simon, Eva, et al.
Publicado: (2012)

Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
por: Böger, Christine, et al.
Publicado: (2014)

Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization
por: Mathiak, Micaela, et al.
Publicado: (2017)

Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis
por: Warneke, V S, et al.
Publicado: (2013)

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
por: Gómez-Martin, Carlos, et al.
Publicado: (2012)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas
por: Ansari, J, et al.
Publicado: (2011)

Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer
por: Shukla, Shailaja, et al.
Publicado: (2016)

Ki67—An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity
por: Böger, Christine, et al.
Publicado: (2015)

HER-2/neu and E-cadherin Expression and Microsatellite Instability in Gastric Dysplasia
por: Ahmadi, L, et al.
Publicado: (2011)

HER2 testing in gastric cancer: results of a German expert meeting
por: Lordick, Florian, et al.
Publicado: (2017)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
por: Böger, Christine, et al.
Publicado: (2017)

Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort
por: Röcken, Christoph, et al.
Publicado: (2016)

Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations
por: Böger, C., et al.
Publicado: (2017)

Interpreting whole genome and exome sequencing data of individual gastric cancer samples
por: Esser, Daniela, et al.
Publicado: (2017)

Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry
por: ZHU, GUANG-JUN, et al.
Publicado: (2014)

Comparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer
por: Pokhrel, Rakesh, et al.
Publicado: (2022)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

LAG3 in gastric cancer: it’s complicated
por: Ulase, Dita, et al.
Publicado: (2023)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India
por: Nadaf, Asmanaz Saleem, et al.
Publicado: (2018)

Troy is expressed in human stomach mucosa and a novel putative prognostic marker of intestinal type gastric cancer
por: Wilhelm, Franziska, et al.
Publicado: (2016)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas
por: Rosa, F.E., et al.
Publicado: (2013)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
por: Böger, Christine, et al.
Publicado: (2016)

MET in gastric cancer – discarding a 10% cutoff rule
por: Metzger, Marie‐Luise, et al.
Publicado: (2015)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications
por: Heckl, Steffen M., et al.
Publicado: (2019)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_33ss3hsqgs2sjbjm9h4trusvh3